K-new drugs Rosuzet·K-CAB dominate the prescription market
By Chon, Seung-Hyun | translator Hong, Ji Yeon
24.10.25 05:55:03
가나다라
0
Rosuzet leads the market for outpatient prescription sales for three consecutive quarters…generated KRW 253.6B in cumulative sales for Q3
K-CAB ranks second for two consecutive quarters…surpassed KRW 50B in quarterly prescription sales
Tagrisso, significant growth in outpatient prescription sales due to expanded reimbursement…Leclaza 86%↑
Pharmaceuticals developed by Korean pharmaceutical companies using their R&D capacities have strengthened their influence on the outpatient prescription market. Quarterly prescription sales of Hanmi Pharmaceutical's new combination drug, Rosuzet, and HK inno.N's K-CAB exceeded KRW 50 billion, ranking at the top. Astra Zeneca's anticancer agent, Tagrisso, also exhibits a high growth rate with its expanded reimbursement.
According to drug market research company IQVIA on October 23rd, Rosuzet, a combination therapy used to treat hyperlipidemia, recorded the highest outpatient prescription amount by generating KRW 53.5 billion. Rosuzet exhibited growth of 17.5% compared to Q3 last year, leading the market for
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)